老人潛在不適當用藥之處方優化：以氫離子幫浦阻斷劑為例

Deprescribing Potentially Inappropriate Medication(s) among Older Adults: Proton Pump Inhibitor as an Example

10.6317/LTC.202212_25(2).0007

吳美慧(Mei-Hui Wu)

氫離子幫浦阻斷劑 ； 老年人 ； 處方優化 ； 系統性回顧 ； proton pump inhibitors ； older adults ； deprescribing ； systematic reviews

長期照護雜誌

25卷2期（2022 / 12 / 01）

185 - 201

英文

多重用藥可能因為潛在不適當用藥與藥物不良事件增加老年人跌倒、身體與認知功能損傷、住院、甚至死亡。長期使用氫離子幫浦阻斷劑（proton pump inhibitor，簡稱PPI）會增加困難梭狀桿菌感染有關的腹瀉、肺炎與骨折的風險。處方優化可管理多重用藥並改善結果。本研究旨在評估對長期使用PPI老年人進行處方優化是安全、有效和可行的介入措施，以改善用藥安全和健康。本研究自電子資料庫（PubMed、EMBASE等）搜尋文獻，包含各資料庫從收錄年代至2019年2月21日。選取符合研究主題：使用PPI持續超過8週之老年人，排除需要PPI提供胃保護者，評估老年人PPI處方優化的影響。符合選取標準納入的研究3篇，結果發現：停止PPI易導致腸胃道症狀復發，達顯著差異。逐漸減少劑量停用PPI的成功率比較高，但未達顯著差異。而需要時使用PPI症狀緩解之比較，未達顯著差異；每日消耗藥丸數量較低，達顯著差異；藥物便利性或主觀滿意度皆未達顯著差異。由於納入的篇數較少，需要更多隨機對照試驗針對此議題進行調查。

Polypharmacy may increase incidents of falls, physical and cognitive impairment, hospitalization and even death due to potentially inappropriate medications and adverse drug events. Chronic use of proton pump inhibitors (PPI) increases the risk of diarrhea associated with Clostridium difficile infections, pneumonia, and fractures. Deprescribing may manage polypharmacy and improve outcomes. The aim of this study is to evaluate the safety, effectiveness and feasibility of the intervention conducted by deprescribing of long-term PPI for the improvement of medication safety and health outcomes among older adults. We searched online electronic databases (e.g., PubMed, EMBASE) from the earliest record to February 21, 2019. The inclusion criteria were the studies that evaluated older adults who took PPI for more than 8 weeks. The exclusion criteria were the necessarily chronic use of PPI to provide gastroprotection. The effects associated with deprescribing PPI in older adults were determined. There were 3 studies that met the inclusion criteria. The results showed the discontinuation method significantly increased the risk of recurrence of gastrointestinal symptoms. The successful discontinuation rate of the tapering method was higher, but without statistical significance. The on-demand method displayed nonsignificant difference for the comparison of symptom alleviation, but significantly lower number of pills consumed daily. No significant differences were found for convenience of medication and subjective satisfaction. Due to the small number of studies included, the result of this meta-analysis in regard to the deprescribing of long-term PPI among older adults is not conclusive. Further randomized controlled trials are required for the exploration of the relevant issues in the future.

1. 林香汶,賴況潔,林志學(2019)。老人潛在不適當用藥之文獻回顧。長期照護雜誌，23(2)，95-110。
   連結：
2. 傅鈺翔,廖宜邡,王昕仁(2020)。藥事照護提升長期照護生活品質指標。長期照護雜誌，24(1)，45-63。
   連結：
3. American Geriatrics Society 2015 Beers Criteria Update Expert Panel(2015).American Geriatrics Society 2015 updated Beers Criteria for potentially inappropriate medication use in older adults.Journal of the American Geriatrics Society,63(11),2227-2246.
4. American Geriatrics Society Beers Criteria Update Expert Panel(2019).American Geriatrics Society 2019 updated AGS Beers Criteria(R) for potentially inappropriate medication use in older adults.Journal of the American Geriatrics Society,67(4),674-694.
5. Avraham, O.,Biglow, M.(2018).Implementation of proton pump inhibitor deprescription protocol in geriatric residents.Annals of Pharmacotherapy,52(8),747-753.
6. Bjerre, L. M.,Farrell, B.,Hogel, M.,Graham, L.,Lemay, G.,McCarthy, L.,Wiens, A.(2018).Deprescribing antipsychotics for behavioural and psychological symptoms of dementia and insomnia: Evidence-based clinical practice guideline.Canadian Family Physician,64(1),17-27.
7. Björnsson, E.,Abrahamsson, H.,Simrén, M.,Mattsson, N.,Jensen, C.,Agerforz, P.,Kilander, A.(2006).Discontinuation of proton pump inhibitors in patients on long-term therapy: A double-blind, placebo-controlled trial.Alimentary Pharmacology and Therapeutics,24(6),945-954.
8. Boghossian, T. A.,Rashid, F. J.,Thompson, W.,Welch, V.,Moayyedi, P.,Rojas-Fernandez, C.,Farrell, B.(2017).Deprescribing versus continuation of chronic proton pump inhibitor use in adults.The Cochrane Database of Systematic Reviews,3(3),CD011969.
9. Casanova, N. M.,Paredes, A. M.,Herrera, S. G.,Urrutia, A. C.,Martinez, M. L.,Gomariz, M. C.(2018).4CPS-006 Effectiveness of multidisciplinary interventions to deprescribe inappropriate proton pump inhibitors in a nursing home.European Journal of Hospital Pharmacy,25(Suppl 1),A44-A44.
10. Cho, J. H.,Koo, J. Y.,Kim, K. O.,Lee, S. H.,Jang, B. I.,Kim, T. N.(2018).On-demand versus half-dose continuous therapy with esomeprazole for maintenance treatment of gastroesophageal reflux disease: A randomized comparative study.Medicine,97(43),e12732.
11. Coffey, C. P.,Barnette, D. J.,Wenzke, J. T.,Lawrence, J.(2019).Implementing a systematic approach to deprescribing proton pump inhibitor therapy in older adults.The Senior Care Pharmacist,34(1),47-55.
12. Desilets, A. R.,Asal, N. J.,Dunican, K. C.(2012).Considerations for the use of proton-pump inhibitors in older adults.Consultant Pharmacist,27(2),114-120.
13. Farrell, B.,Black, C.,Thompson, W.,McCarthy, L.,Rojas-Fernandez, C.,Lochnan, H.,Welch, V.(2017).Deprescribing antihyperglycemic agents in older persons: Evidence-based clinical practice guideline.Canadian Family Physician,63(11),832-843.
14. Farrell, B.,Pottie, K.,Thompson, W.,Boghossian, T.,Pizzola, L.,Rashid, F. J.,Moayyedi, P.(2017).Deprescribing proton pump inhibitors: Evidence-based clinical practice guideline.Canadian Family Physician,63(5),354-364.
15. Lambert, A. A.,Lam, J. O.,Paik, J. J.,Ugarte-Gil, C.,Drummond, M. B.,Crowell, T. A.(2015).Risk of community-acquired pneumonia with outpatient proton-pump inhibitor therapy: A systematic review and meta-analysis.PloS One,10(6),e0128004.
16. Lee, C.,Lo, A.,Ubhi, K.,Milewski, M.(2017).Outcome after discontinuation of proton pump inhibitors at a residential care site: Quality improvement project.Canadian Journal of Hospital Pharmacy,70(3),215-223.
17. Pilotto, A.,Leandro, G.,Franceschi, M.(2003).Short- and long-term therapy for reflux oesophagitis in the elderly: A multi-centre, placebo-controlled study with pantoprazole.Alimentary Pharmacology and Therapeutics,17(11),1399-1406.
18. Pottie, K.,Thompson, W.,Davies, S.,Grenier, J.,Sadowski, C. A.,Welch, V.,Farrell, B.(2018).Deprescribing benzodiazepine receptor agonists: Evidence-based clinical practice guideline.Canadian Family Physician,64(5),339-351.
19. Qato, D. M.,Wilder, J.,Schumm, L. P.,Gillet, V.,Alexander, G. C.(2016).Changes in prescription and over-the-counter medication and dietary supplement use among older adults in the United States, 2005 vs 2011.JAMA Internal Medicine,176(4),473-482.
20. Reeve, E.,Farrell, B.,Thompson, W.,Herrmann, N.,Sketris, I.,Magin, P. J.,Hilmer, S. N.(2019).Deprescribing cholinesterase inhibitors and memantine in dementia: guideline summary.Medical Journal of Australia,210(4),174-179.
21. Reeve, E.,Thompson, W.,Farrell, B.(2017).Deprescribing: A narrative review of the evidence and practical recommendations for recognizing opportunities and taking action.European Journal of Internal Medicine,38,3-11.
22. Scott, I. A.,Hilmer, S. N.,Reeve, E.,Potter, K.,Le Couteur, D.,Rigby, D.,Martin, J. H.(2015).Reducing inappropriate polypharmacy: the process of deprescribing.JAMA Internal Medicine,175(5),827-834.
23. Thompson, W.,Farrell, B.(2013).Deprescribing: what is it and what does the evidence tell us?.The Canadian Journal of Hospital Pharmacy,66(3),201-202.
24. Wahking, R. A.,Steele, R. L.,Hanners, R. E.,Lockwood, S. M.,Davis, K. W.(2018).Outcomes from a pharmacist - led proton pump inhibitor stewardship program at a single institution.Hospital Pharmacy,53(1),59-67.
25. Walsh, K.,Kwan, D.,Marr, P.,Papoushek, C.,Lyon, W. K.(2016).Deprescribing in a family health team: A study of chronic proton pump inhibitor use.Journal of Primary Health Care,8(2),164-171.
26. 內政部統計處（2018，4 月 14 日）。最新統計指標。取自 https://www.moi.gov.tw/stat/chart.aspx
27. 李珮甄,周月卿,陳曾基(2017)。淺談處方優化：deprescribing。家庭醫學與基層醫療，32(10)，291-297。
28. 林家聿,雷才萱,曾啟庭,陳立奇(2017)。某區域醫院口服氫離子幫浦抑制劑(PPIs)的藥品使用分析。106 年度社團法人臺灣臨床藥學會第 14 屆第 2 次會員代表大會暨學術研討會，台中市、中華民國:
29. 衛生福利部（2022）。 111 年度一般護理之家評鑑基準。取自 https://dep.mohw.gov.tw/DONAHC/lp-3850-104.html
30. 顏祥,黃輝慶,林俊宏,吳佩霖,羅惠珍(2018)。老年人潛在性不當用藥準則 STOPP Version 2 Criteria 繁體中文版的發展與驗證。臺灣臨床藥學雜誌，26(4)，282-294。